Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
St. Jude Autologous Genome Edited Stem Cells For Sickle Cell Disease-1
NCT06506461Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in sickle cell disease (SCD), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Incidence of neutrophil engraftment at 42 days, Incidence of platelet engraftment at 60 days and 3 more. Started Mar 2025; status: recruiting.
02
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06506461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06506461.